146 related articles for article (PubMed ID: 34273028)
1. ARA-linker-TGFαL3: a novel chimera protein to target breast cancer cells.
Ghadaksaz A; Imani Fooladi AA; Mahmoodzadeh Hosseini H; Nejad Satari T; Amin M
Med Oncol; 2021 Jul; 38(8):96. PubMed ID: 34273028
[TBL] [Abstract][Full Text] [Related]
2. Targeting the EGFR in cancer cells by fusion protein consisting of arazyme and third loop of TGF-alpha: an in silico study.
Ghadaksaz A; Imani Fooladi AA; Mahmoodzadeh Hosseini H; Nejad Satari T; Amin M
J Biomol Struct Dyn; 2022; 40(22):11744-11757. PubMed ID: 34379041
[TBL] [Abstract][Full Text] [Related]
3. Growth-inhibitory effects of TGFαL3-SEB chimeric protein on colon cancer cell line.
Maleki F; Sadeghifard N; Hosseini HM; Bakhtiyari S; Goleij Z; Behzadi E; Sedighian H; Imani Fooladi AA
Biomed Pharmacother; 2019 Feb; 110():190-196. PubMed ID: 30471512
[TBL] [Abstract][Full Text] [Related]
4. TGFαL3-SEB fusion protein as an anticancer against ovarian cancer.
Maleki F; Sadeghifard N; Sedighian H; Bakhtiyari S; Hosseini HM; Fooladi AAI
Eur J Pharmacol; 2020 Mar; 870():172919. PubMed ID: 31935394
[TBL] [Abstract][Full Text] [Related]
5. Preparation and In Vitro Evaluation of Antitumor Activity of TGFαL3-SEB as a Ligand-Targeted Superantigen.
Yousefi F; Mousavi SF; Siadat SD; Aslani MM; Amani J; Rad HS; Fooladi AA
Technol Cancer Res Treat; 2016 Apr; 15(2):215-26. PubMed ID: 25759426
[TBL] [Abstract][Full Text] [Related]
6. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death.
Dent P; Reardon DB; Park JS; Bowers G; Logsdon C; Valerie K; Schmidt-Ullrich R
Mol Biol Cell; 1999 Aug; 10(8):2493-506. PubMed ID: 10436007
[TBL] [Abstract][Full Text] [Related]
7. Targeting glioblastoma multiforme using a novel fusion protein comprising interleukin-13 and staphylococcal enterotoxin B in vitro.
Gholipour Z; Fooladi AAI; Parivar K; Halabian R
Toxicol In Vitro; 2023 Oct; 92():105651. PubMed ID: 37482138
[TBL] [Abstract][Full Text] [Related]
8. A novel EGFR-specific recombinant ricin-panitumumab (scFv) immunotoxin against breast and colorectal cancer cell lines; in silico and in vitro analyses.
Naemi AA; Salmanian AH; Noormohammadi Z; Amani J
Eur J Pharmacol; 2023 Sep; 955():175894. PubMed ID: 37429519
[TBL] [Abstract][Full Text] [Related]
9. In silico and experimental methods for designing a potent anticancer arazyme-herceptin fusion protein in HER2-positive breast cancer.
Rahmani F; Imani Fooladi AA; Ajoudanifar H; Soleimani NA
J Mol Model; 2023 Apr; 29(5):160. PubMed ID: 37103612
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models.
Gupta P; Srivastava SK
BMC Med; 2012 Jul; 10():80. PubMed ID: 22824293
[TBL] [Abstract][Full Text] [Related]
11. ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells.
Nautiyal J; Yu Y; Aboukameel A; Kanwar SS; Das JK; Du J; Patel BB; Sarkar FH; Rishi AK; Mohammad RM; Majumdar AP
Mol Cancer Ther; 2010 Jun; 9(6):1503-14. PubMed ID: 20515951
[TBL] [Abstract][Full Text] [Related]
12. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
[TBL] [Abstract][Full Text] [Related]
13. Anti-cancer effects of recombinant arazyme from Serratia Proteomaculans.
Amjadi G; Parivar K; Fazlollah Mousavi S; Imani Fooladi AA
J BUON; 2020; 25(1):531-542. PubMed ID: 32277680
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of Pinkbar/pAKT and MMP2/MMP9 Expression in MDA-MB-231 Breast Cancer Cells as Potential Targets in Cancer Therapy by hAMSCs Secretome.
Shakery T; Safari F
Cells Tissues Organs; 2023; 212(2):155-163. PubMed ID: 34695828
[TBL] [Abstract][Full Text] [Related]
15. Clostridium difficile toxin B recombinant protein inhibits tumor growth and induces apoptosis through inhibiting Bcl-2 expression, triggering inflammatory responses and activating C-erbB-2 and Cox-2 expression in breast cancer mouse model.
Zhang Y; Li Y; Li H; Chen W; Liu W
Biomed Pharmacother; 2018 May; 101():391-398. PubMed ID: 29501042
[TBL] [Abstract][Full Text] [Related]
16. Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression.
Orlando UD; Castillo AF; Medrano MAR; Solano AR; Maloberti PM; Podesta EJ
Biochem Pharmacol; 2019 Jan; 159():52-63. PubMed ID: 30414939
[TBL] [Abstract][Full Text] [Related]
17. Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer.
El Guerrab A; Zegrour R; Nemlin CC; Vigier F; Cayre A; Penault-Llorca F; Rossignol F; Bignon YJ
PLoS One; 2011; 6(9):e25080. PubMed ID: 21966417
[TBL] [Abstract][Full Text] [Related]
18. Thieno[2,3-d]pyrimidin-4(3H)-one Derivatives of Benzimidazole as Potential Anti- Breast Cancer (MDA-MB-231, MCF-7) Agents.
Dimov S; Mavrova AT; Yancheva D; Nikolova B; Tsoneva I
Anticancer Agents Med Chem; 2021; 21(11):1441-1450. PubMed ID: 32698751
[TBL] [Abstract][Full Text] [Related]
19. TGFα-EGFR pathway in breast carcinogenesis, association with WWOX expression and estrogen activation.
Pospiech K; Orzechowska M; Nowakowska M; Anusewicz D; Płuciennik E; Kośla K; Bednarek AK
J Appl Genet; 2022 May; 63(2):339-359. PubMed ID: 35290621
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells.
Xu H; Yu Y; Marciniak D; Rishi AK; Sarkar FH; Kucuk O; Majumdar AP
Mol Cancer Ther; 2005 Mar; 4(3):435-42. PubMed ID: 15767552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
